Aptus Pharma Promotes Baby Care at Rajkot Airport

Aptus Pharma Limited has undertaken a strategic brand-building initiative by taking over the Baby Care Room at Rajkot Hirasar Airport. This move is aimed at promoting the company's upcoming baby care and OTC product portfolio. The initiative was disclosed to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company stated that this premium placement at one of Gujarat's growing airports is designed to enhance brand visibility among travelers and families. By securing this location, Aptus Pharma aims to strengthen awareness of its expanding healthcare product range. The focus is on establishing a stronger presence in the OTC and baby care segment.

Strategic Objectives

The initiative is expected to contribute positively towards the company's brand positioning and market presence. Management believes that the visibility at the airport will aid in improving market reach and strengthening customer trust. The company described the initiative as part of the ordinary course of business.

Operational Divisions

Aptus Pharma operates through several divisions to manage its diverse product portfolio. These divisions include:

Division Name	Focus Area
Aptus Pharma	Pioneer Division
APTUS CD CARE	Cardiac Diabetic Division
APTUS WellCare	Health And Personal Care Division
APTUS Global	Export Division

The brand promotion at Rajkot Hirasar Airport aligns with the company's broader strategy to expand its footprint in the healthcare and personal care markets.

Aptus Pharma Limited has disclosed a series of transactions involving the transfer of equity shares among members of its promoter group. The company submitted these details to the BSE in compliance with Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The disclosures were made by Tejash Maheshchandra Hathi, the Managing Director of the company.

Transaction Details

The transactions were classified as off-market inter-se transfers among the promoter group. These trades were executed on the BSE on May 11, 2026. The company received intimations regarding these changes in shareholding on May 13, 2026. The disclosures detail the acquisition and disposal of shares by various promoters, altering their respective percentage holdings in the pharmaceutical company.

Changes in Promoter Holdings

The disclosures outline the specific number of shares bought and sold by individual promoters, along with the corresponding values and the resulting post-transaction shareholding percentages. The table below summarizes the key changes in the shareholding patterns of the identified promoters.

Promoter Name	Type	Shares Transacted	Transaction Value	Pre-Transaction Holding	Post-Transaction Holding
Chattrabhujat Butani	Sale	124000	43400000	2,25,000 (3.28%)	101000 (1.47%)
Gaurang Rameshchandra Thakker	Purchase	18000	6300000	575000 (8.38%)	593000 (8.64%)
Ghanshyam Vinubhai Pansuriya	Purchase	14000	49000000	350000 (5.10%)	364000 (5.31%)
Mr. Kapil Chandarana	Purchase	10000	3500000	775000 (11.30%)	785000 (11.44%)
Kripaliben Mayank Thakker	Purchase	18000	6300000	575000 (8.38%)	593000 (8.64%)
Milly Chetan Lalseta	Purchase	18000	6300000	575000 (8.38%)	593000 (8.64%)
Riddhish Natwarlal Tanna	Purchase	18000	6300000	575000 (8.38%)	593000 (8.64%)
Mr. Tejasbhai Hathi	Purchase	10000	3500000	775000 (11.30%)	785000 (11.44%)
Kunjal Piyushbhai Unadkat	Purchase	18000	6300000	575000 (8.38%)	593000 (8.64%)

Regulatory Compliance

The company confirmed that there were no trades in derivatives by the promoters or their immediate relatives during the period under review. The disclosures were signed and submitted by the Managing Director, Tejash Maheshchandra Hathi, on May 15, 2026, from Rajkot. The filings ensure compliance with the continual disclosure requirements mandated by the market regulator for listed entities.